Aducanumab Filed In Japan Despite Recent US Setback
Large Market Awaits If Approved
Executive Summary
Biogen pushes ahead with approval submission in potentially large Japanese market, despite the negative views of a recent advisory committee in the US.
You may also be interested in...
Aducanumab Approval Decision Delayed: Could This Be Good News?
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.
Rare Liver Disease Drug Contenders Among Latest EU Filings
Among the 13 new drug marketing applications that the European Medicines Agency has most recently accepted for review are two products that could become the first approved treatments for children with progressive familial intrahepatic cholestasis, a life-threatening disorder.
Third Time Lucky As Japan Finally Approves Shionogi’s Oral COVID Antiviral
Shionogi’s once-daily oral COVID-19 antiviral finally gets Japan approval after being considered for the third time by an expert panel, paving the way for public availability of the country’s first such home-grown option in early December.